Company News: NEO New Oncology AG begins clinical study on molecular diagnostics for lung cancer patients

NEO New Oncology AG announced today the launch of its prospective registry “NEOlung”. In this study, approximately 1,500 patients with advanced or metastatic lung cancer will gain direct and timely access to comprehensive molecular diagnostics and close-to-home care in specialized centers in Northern Germany.

With NEOlung, NEO New Oncology AG will employ its NEO technology to offer comprehensive tumor analysis in addition to standard histopathological diagnosis for each participating patient. NEO is able to provide rapid and comprehensive analysis of all therapeutically-relevant genetic alterations from either a blood sample or a minimal quantity of tissue. In addition to point mutations, both translocations and copy number changes, all of which play an increasingly important role in the treatment of lung cancer, are detected. The aim of NEOlung is to establish a prospective, non-interventional registry in order to evaluate the quality and performance of the NEO technology in its ability to detect therapeutically relevant genomic alterations. Furthermore, the efficacy of treatment using targeted substances in different lines of therapy, the progression of tumor diseases and the emergence of resistances in clinical practice will be recorded prospectively. Data pertaining to health economics will also be collected and evaluated. Finally, NEO will be compared to standard molecular diagnostics methods as well. NEOlung is financed by NEO New Oncology AG.

NEOlung will be performed at centers of the NOWEL network, which aims to ensure optimal, region-wide accessible care for lung cancer patients across all of Northern Germany.